Navigation Links
Phosphagenics Initiates U.S. Clinical Trials for Its Topical Retinoic Acid
Date:2/19/2008

c acid. Despite this, the U.S. market for topical prescription retinoids, such as retinoic acid, for acne treatment exceeds US$300 million annually.

"A new formulation with the ability to deliver greater absorption of retinoic acid, reduce irritation and dryness and limit systemic circulation would significantly increase practitioners' flexibility in prescribing the product," said Harry Rosen, President & CEO of Phosphagenics. "It would enable physicians to prescribe greater doses of retinoic acid and/or maintain current dosing while achieving improved efficacy and substantially limiting adverse effects. Such a product would have the potential to expand the current market, and would likely capture a significant proportion of the existing market.

"In our previously completed pre-clinical studies, we were able to consistently demonstrate an increase in retinoic acid delivered, a reduction in irritation scores, as well as limit the delivery of retinoic acid into the systemic circulation, which is important because of its side effects. Our objective is to replicate these results in our human trial and deliver a safer, more effective acne treatment to consumers as quickly as possible."

In addition to retinoic acid, Phosphagenics is developing a number of other product candidates utilizing its targeted, non-systemic delivery technology, including multiple anti-inflammatory and analgesic compounds.

About Phosphagenics Limited

Phosphagenics is a Melbourne-based, globally driven biotechnology company focused on the discovery of new and cost effective ways to enhance the bioavailability, activity, safety and delivery of proven pharmaceutical and nutraceutical products.

Phosphagenics' core technology is built around the science and application of phosphorylation, a process where the addition of a phosphate group has been found to enhance the bioavailability, activity and safety of existing pharmaceuticals and nutraceuticals, as well as
'/>"/>

SOURCE Phosphagenics Limited
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Update on Progression of Phosphagenics and Nestle Nutritions Phospha E(R) Trial
2. Nestle Nutrition and Phosphagenics to Commence Phospha E(R) Phase 2 Clinical Trial
3. Phosphagenics to Conduct a Phase 1 Transdermal Oxycodone Clinical Trial
4. Phosphagenics to Commence Phase 2 TPM/Insulin Clinical Trial
5. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
6. Alexza Initiates AZ-007 (Staccato(R) Zaleplon) Phase 1 Clinical Trial and Updates Clinical Pipeline Development Status
7. Tigris Pharmaceuticals Initiates Phase I Study of AFP-464 in Patients with Solid Tumors
8. Nuvelo Initiates Phase 1 Clinical Trial of Thrombin Inhibitor, NU172
9. Northwestern Memorial Transplant Program Initiates New Study
10. Cerimon Pharmaceuticals Initiates Phase II/III Clinical Studies to Evaluate its Diclofenac Patch for Mild to Moderate Pain
11. SGX Initiates Phase I Trials for SGX523
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/27/2015)... and MENLO PARK, Calif. , ... (OTCQX: DMPI) ("DelMar" and the "Company"), a ... cancer therapies in new orphan drug indications, today ... and accredited investors for a registered direct placement ... and 3.35 million common stock purchase warrants for ...
(Date:7/27/2015)... --  DocResponse was ranked the most accurate ... peer-reviewed study , "Evaluation of symptom checkers for ... the July issue of The British Medical Journal ... researchers determined that performance of online symptom checkers ... first in standardized patient evaluations more often than ...
(Date:7/27/2015)... Research and Markets ( http://www.researchandmarkets.com/research/7lz2fk/intraoperative ) has ... by Type (Intraoperative CT, Intraoperative MRI, Intraoperative Ultrasound) , ... Forecast to 2019" report to their offering. ... value of $2.1 Billion by 2019 from $1.8 Billion ... forecast period. The intraoperative imaging market ...
Breaking Medicine Technology:DelMar Pharmaceuticals Announces Financing Update and Initial Subscriptions of $2.0 million in Registered Direct Offering 2DelMar Pharmaceuticals Announces Financing Update and Initial Subscriptions of $2.0 million in Registered Direct Offering 3Harvard Study Finds DocResponse Most Accurate Medical Symptom Checker/Diagnostics Application 2Harvard Study Finds DocResponse Most Accurate Medical Symptom Checker/Diagnostics Application 3Global Intraoperative Imaging (Intraoperative CT, Intraoperative MRI, Intraoperative Ultrasound) Market Forecasts & Trends 2015-2019 2
... 17, 2012  Boston Scientific Corporation (NYSE: BSX ... market launch of the Epic™ Vascular Self-Expanding Stent System.  ... in patients with iliac artery stenosis, a form of ... by insufficient blood flow.  "The Epic ...
... RARITAN, N.J., May 17, 2012 Janssen Pharmaceuticals, ... Phase 3 study suggesting NUCYNTA® ER (tapentadol) extended-release ... providing pain management among adults with chronic moderate ... of the study were presented at the 31st ...
Cached Medicine Technology:Boston Scientific Announces FDA Approval and U.S. Launch of EPIC™ Vascular Stent 2Boston Scientific Announces FDA Approval and U.S. Launch of EPIC™ Vascular Stent 3Boston Scientific Announces FDA Approval and U.S. Launch of EPIC™ Vascular Stent 4Boston Scientific Announces FDA Approval and U.S. Launch of EPIC™ Vascular Stent 5Phase 3 Data Show NUCYNTA® ER (tapentadol) Extended-Release Tablets Provide Pain Management for Patients with Diabetic Peripheral Neuropathy (DPN) 2Phase 3 Data Show NUCYNTA® ER (tapentadol) Extended-Release Tablets Provide Pain Management for Patients with Diabetic Peripheral Neuropathy (DPN) 3Phase 3 Data Show NUCYNTA® ER (tapentadol) Extended-Release Tablets Provide Pain Management for Patients with Diabetic Peripheral Neuropathy (DPN) 4Phase 3 Data Show NUCYNTA® ER (tapentadol) Extended-Release Tablets Provide Pain Management for Patients with Diabetic Peripheral Neuropathy (DPN) 5Phase 3 Data Show NUCYNTA® ER (tapentadol) Extended-Release Tablets Provide Pain Management for Patients with Diabetic Peripheral Neuropathy (DPN) 6Phase 3 Data Show NUCYNTA® ER (tapentadol) Extended-Release Tablets Provide Pain Management for Patients with Diabetic Peripheral Neuropathy (DPN) 7Phase 3 Data Show NUCYNTA® ER (tapentadol) Extended-Release Tablets Provide Pain Management for Patients with Diabetic Peripheral Neuropathy (DPN) 8Phase 3 Data Show NUCYNTA® ER (tapentadol) Extended-Release Tablets Provide Pain Management for Patients with Diabetic Peripheral Neuropathy (DPN) 9Phase 3 Data Show NUCYNTA® ER (tapentadol) Extended-Release Tablets Provide Pain Management for Patients with Diabetic Peripheral Neuropathy (DPN) 10Phase 3 Data Show NUCYNTA® ER (tapentadol) Extended-Release Tablets Provide Pain Management for Patients with Diabetic Peripheral Neuropathy (DPN) 11Phase 3 Data Show NUCYNTA® ER (tapentadol) Extended-Release Tablets Provide Pain Management for Patients with Diabetic Peripheral Neuropathy (DPN) 12
(Date:7/27/2015)... ... 27, 2015 , ... The heroin epidemic is affecting the Charlotte in North ... 7th. The rate for heroin usage has continued to climb around the country in ... less expensive alternative for those with an addiction to prescription opiate medications. According to ...
(Date:7/27/2015)... ... , ... On July 14, 2015, Harper’s Bazaar Magazine in an article titled ... such as stretch marks , fine lines , and acne scars ... listed include lasers, ultrasound, radio frequency, Botox, and dermal fillers. It is pointed out ...
(Date:7/27/2015)... ... July 27, 2015 , ... The Maricopa Community Colleges ... of the foster care system to get into and complete college. , The ... introduced at an event today with partners from across the valley. , The initiative ...
(Date:7/27/2015)... ... July 27, 2015 , ... ... Calcium Propionate industry is a professional and in-depth research report. The report ... chain structure, international market analysis etc. This report covers the global (US, ...
(Date:7/27/2015)... , ... July 27, 2015 , ... Throughout its 20 ... premier doctors and medical providers working on a lien basis. As the personal ... wide range of providers from chiropractors, to orthopedists, to pain management physicians, to psychologists ...
Breaking Medicine News(10 mins):Health News:45% Of People Addicted to Heroin Began Addicted to Prescription Medications 2Health News:45% Of People Addicted to Heroin Began Addicted to Prescription Medications 3Health News:The Latest Treatment Options for Seven Common Skin Issues 2Health News:Maricopa Community Colleges Launch Program To Help Youth In Foster Care Finish College 2Health News:Maricopa Community Colleges Launch Program To Help Youth In Foster Care Finish College 3Health News:Calcium Propionate Market Global Suppliers and Manufacture Analysis 2Health News:Calcium Propionate Market Global Suppliers and Manufacture Analysis 3Health News:Doctors on Liens Adds Highly Respected Physical Therapy Office in Los Angeles 2
... Sept. 9 As the nation awaits President Obama,s address ... The Philanthropic Collaborative (TPC) sent today a letter to the ... community foundations in the field of health. , , ... in the social and economic effectiveness of health-related philanthropic activities. ...
... that the sexual transmitted infection known as Trichomonas ... prostate cancer in a study published online September 9 ... . Jennifer Rider Stark, ScD, of the department ... in Boston, and colleagues conducted a case-control study nested ...
... , , , WASHINGTON, Sept. ... guest of President Barack Obama tonight for the President,s historic speech ... nation. , , As Co-Chair of the ... spearheading a bold campaign encouraging mayors around the country to urge ...
... Imaging technology might advance treatment of psychotic disorders, researchers ... technology has helped researchers pinpoint the part of the ... as schizophrenia begin, a new study says. , The ... in their early stages and help scientists develop more ...
... Republican Congressman Slated to Oppose President Obama,s Health Care Plan ... , , WASHINGTON, Sept. 9 Public ... Charles Boustany (R-La.) and the expected opposing remarks he will deliver ... session of Congress on health care reform. , , ...
... , , , KEYSTONE TREATMENT AND ... SIMILAR EVENTS TO FOLLOW AT CANTON AT 1 PM: , ... Media welcome at both locations , , SIOUX ... Sioux Falls, S.D. will be the 2009 national headquarters at 11 AM Wednesday, ...
Cached Medicine News:Health News:In Letter to President, TPC Highlights Foundation Grants in Health 2Health News:In Letter to President, TPC Highlights Foundation Grants in Health 3Health News:JNCI news brief: STD confirmed to be associated with increased risk of prostate cancer 2Health News:Mayor Gavin Newsom to Be President Obama's Guest for Healthcare Reform Speech to the Nation 2Health News:Brain Scans Could Help Spot Schizophrenia Earlier 2Health News:Rep. Boustany Hauled in $1.25 Million From Health and Insurance Industry 2Health News:Wed., Sept. 16, 11 AM News Conference: Sioux Falls' Keystone Treatment Center Is National HQ to Lead 100 Locations Nationwide in Balloon Liftoff Celebrating Recovery Against New Wave of Drug Abuse; Former U.S. Drug Czar/4-Star Gen. Barry McCaffrey, Lieute 2
... The REFLEXION 1st MPJ IMPLANT SYSTEM ... the primary reconstruction of the 1st metatarsal ... traumatic arthritis or revision of a previous ... achieve three goals: pain relief, superior function ...
... The hands play an important part in ... impairments and rheumatic changes can cause severe ... of the finger-joint prostheses was to produce ... the natural function as nearly possible.,The cementless ...
... The OSTEOMED 3.0/4.0mm CANNULATED SCREW SYSTEM ... Orthopedic Hand surgeon and Podiatrist, can be ... fusions. The system features two simplified ... Both screw sizes utilize one unique set ...
... the lower extremity for prepping before hip or ... procedures and particularly helpful for supporting the leg ... By holding the foot/ankle in an externally rotated ... which helps eliminate the need for manual support.,The ...
Medicine Products: